产品编号：X745500
产品规格：5mg
产品价格：面议
| 标准品编号: | X745500 |
| 名称: | XL184 |
| 别名: | Cabozantinib; N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; BMS 907351; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
| CAS号: | 849217-68-1 |
| 分子式: | C₂₈H₂₄FN₃O₅ |
| 外观: | 白色固体 |
| 熔点: | 212-215°C |
| 分子量: | 501.51 |
| 储存: | -20°C Freezer |
| 溶解度: | DMSO (Slightly), Methanol (Slightly, Heated) |
| 类别: | Standards; Pharmaceutical/API Drug Impurities/Metabolites; |
| 应用: | XL184 can be used in biological study. Computational network biological approach based on pathway cross-talk inhibition identified new synergistic drug combinations using raloxifene and cabozantinib for treatment of human breast cancer in xenograft mouse model. Potent c-MET inhibitor. |
| 参考文献 | |
